Provided by Tiger Trade Technology Pte. Ltd.

Nuvation Bio, Inc.

8.52
-0.1400-1.62%
Post-market: 8.44-0.0800-0.94%19:56 EST
Volume:5.18M
Turnover:44.53M
Market Cap:2.92B
PE:-13.31
High:8.88
Open:8.66
Low:8.41
Close:8.66
52wk High:8.95
52wk Low:1.54
Shares:342.83M
Float Shares:231.05M
Volume Ratio:0.88
T/O Rate:2.24%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6400
EPS(LYR):-2.1131
ROE:-52.49%
ROA:-24.82%
PB:8.96
PE(LYR):-4.03

Loading ...

Nuvation Bio (NUVB): Reassessing Valuation After a Powerful Multi‑Year Share Price Rebound

Simply Wall St.
·
11 hours ago

Nuvation Bio Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Dec 11

Nuvation Bio Inc. : H.c. Wainwright Raises Target Price to $18 From $10

THOMSON REUTERS
·
Dec 11

Why Nuvation Bio (NUVB) Is Up 6.5% After Strong Safusidenib Phase 2 Glioma Data And What's Next

Simply Wall St.
·
Dec 07

Innovent Announces Inclusion of Seven Innovative Drugs Including Tyvyt New Indication and Sycume in China's National Reimbursement Drug List

THOMSON REUTERS
·
Dec 07

Nuvation Bio Chief Medical Officer Dongfang Liu Reports Sale of Common Shares

Reuters
·
Dec 04

BUZZ-U.S. STOCKS ON THE MOVE-Spirit AeroSystems, Boeing, Roblox

Reuters
·
Dec 04

BUZZ-U.S. STOCKS ON THE MOVE-Microsoft, Wyndham Hotels & Resorts, Daktronics

Reuters
·
Dec 03

BUZZ-Nuvation Bio rises on brain cancer drug data

Reuters
·
Dec 03

Nuvation Bio Reports Positive Phase 2 Results for Safusidenib in IDH1-Mutant Glioma

Reuters
·
Dec 03

Nuvation Bio Announces Publication of Positive Phase 2 Study Results for Safusidenib for the Treatment of Grade 2 Idh1-Mutant Glioma in Neuro-Oncology

THOMSON REUTERS
·
Dec 03

Nuvation Bio Inc. highlights pipeline progress and IBTROZI launch in oncology-focused corporate presentation

Reuters
·
Dec 01

Nuvation Bio Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow Jones
·
Dec 01

Truist Financial Sticks to Their Buy Rating for Nuvation Bio (NUVB)

TIPRANKS
·
Nov 30

Nuvation Bio Executives to Join Fireside Chats at Major Healthcare Investor Conferences

Reuters
·
Nov 27

Nuvation Bio to discontinue development of NUV-1511

TIPRANKS
·
Nov 27

Clear Street says thesis intact after Nuvation’s NUV-1511 discontinued

TIPRANKS
·
Nov 27

Nuvation Bio Inc - Discontinues Development of Nuv-1511 - SEC Filing

THOMSON REUTERS
·
Nov 26

Nuvation Bio: Nuv-1511 Well Tolerated, Did Demonstrate Promising Signals in Some Patients

THOMSON REUTERS
·
Nov 26

Nuvation Bio Inc: Co Has Made This Decision Due to Lack of Sufficiently Consistent Efficacy Across Cohorts

THOMSON REUTERS
·
Nov 26